Harvard teaching hospital to pay $10 million to settle research misconduct allegations – Retraction Watch (blog)
By raymumme
Piero Anversa
Brigham and Womens Hospital and its parent healthcare network have agreed to pay $10 million to the U.S. government to resolve allegations it fraudulently obtained federal funding.
The case, which involves three former Harvard stem cell researchers, dates back several years. In 2014, Circulation retracted a paper by Piero Anversa, Annarosa Leri, and Jan Kajstura, among others, amidst a university investigation into misconduct allegations. Anversa and Leri whose lab was described as filled with fear by one former research fellow later sued the hospital for notifying journals of that investigation. They lost.
In the agreement announced today by the Department of Justice (DOJ), Partners Healthcare and Brigham and Womens Hospital have agreed to pay the government $10 million to settle allegations that the researchers fraudulently obtained funding from the National Institutes of Health:
The settlement resolves allegations that Dr. Anversa, along with Dr. Annarosa Leri and Dr. Jan Kajstura, knew or should have known that their laboratory promulgated and relied upon manipulated and falsified information, including confocal microscope images and carbon-14 age data for cells, in applications submitted for NIH research grant awards concerning the purported ability of stem cells to repair damage to the heart. The government alleges that problems with the work of the laboratory included improper protocols, invalid and inaccurately characterized cardiac stem cells, reckless or deliberately misleading record-keeping, and discrepancies and/or fabrication of data and images included in applications and publications. The government contends that, at the direction of these BWH scientists, the Anversa laboratory included false scientific information in claims to NIH in order to obtain and use funds from NIH grants.
John Thomas, a partner with Gentry Locke who represents whistleblowers who raise allegations of misconduct, told us that other cases have settled for large amounts such as a recent settlement with Columbia University for $9.5 million. But there are other elements that make this latest announcement noteworthy, he said.
Specifically, most settlements involve some black and white failure in research administration, such as misrepresenting a researchers qualifications on a grant, misreporting effort, or conducting the research at a different facility (such as the Columbia case), said Thomas. The latest decision, in contrast, goes to the science itself.
As a result, he said:
This demonstrates the government is still willing to step in even when its not an administrative issue, even when it goes to the merits of the actual misconduct allegations. I think it shows that when the government awards grants, one of the things its intending to get is good and honest science. The science matters.
We reached out to Anversa and Levi; in response, we received a statement from their attorney:
It is outrageous that BWH has sought to unfairly tarnish the reputations of Drs Anversa and Leri, scientists who have pioneered groundbreaking work in cardiac stem cell reproduction and who have litigation pending against BWH and its president, Betsy Nabel.
Neither Dr. Anversa nor Dr. Leri was involved in the settlement process. BWH self-reported allegations in its own way for its own purposes. It has long been known that Drs. Anversa and Leri relied on the work of a senior scientist in the lab in presenting data for grants and in publications. No one has ever shown that either Dr. Anversa or Dr. Leri participated in the fraud or was aware of it at the time.
BWHs allegations and settlement cannot take away from Drs. Anversa and Leris contributions to the science of stem cell replication. There are Phase II trials being conducted by NIH currently on stem cell treatments based on their work. Taxpayer money was rightly used to further the fight against heart disease, a leading cause of death in this country.
According to the U.S. Attorneys Office, Brigham and Womens Hospital brought the allegations to the governments attention:
After learning of the allegations of research misconduct in the Anversa laboratory, BWH investigated the allegations, disclosed its concerns to the U.S. Department of Health and Human Services, Office of the Inspector General (OIG) and Office of Research Integrity, and then worked cooperatively with OIG and the Department of Justice to explain the bases for the allegations.
The three researchers Anversa, Leri, and Kajstura are no longer based at Brigham and Womens Hospital. Earlier this year, Anversa and Leri published a paper about cardiac progenitor cells that lists an affiliation at the Swiss Institute for Regenerative Medicine.
In todays statement, Acting U.S. Attorney William D. Weinreb said:
Individuals and institutions that receive research funding from NIH have an obligation to conduct their research honestly and not to alter results to conform with unproven hypotheses.
Like Retraction Watch? Consider making atax-deductible contribution to support our growth. You can also follow uson Twitter, like uson Facebook, add us to yourRSS reader, sign up on ourhomepagefor an email every time theres a new post, or subscribe to ourdaily digest. Clickhere to review our Comments Policy. For a sneak peek at what were working on,click here.
Originally posted here:
Harvard teaching hospital to pay $10 million to settle research misconduct allegations - Retraction Watch (blog)
- Developing the Cell-Based Therapies of the Future - University of Miami - November 15th, 2024
- Advancing heart stem cell therapy - UHN Foundation - November 15th, 2024
- Heart defects affect 40,000 US babies every year but cutting edge AI and stem cell tech will save lives and even cure them in the womb - New York... - November 15th, 2024
- Science Is Finding Ways to Regenerate Your Heart - The Wall Street Journal - November 6th, 2024
- AIIMS Bathinda Makes Breakthrough in Stem Cell Therapy Research for Heart Ailments - Elets - October 21st, 2024
- USC launches collaboration with StemCardia to advance heart regeneration therapies - University of Southern California - October 13th, 2024
- The heart is a resident tissue for hematopoietic stem and progenitor cells in zebrafish - Nature.com - September 3rd, 2024
- Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer - July 16th, 2024
- Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome... - July 16th, 2024
- AstraZeneca Closes Acquisition of Amolyt Pharma - July 16th, 2024
- Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) - July 16th, 2024
- Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - July 16th, 2024
- ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder - July 16th, 2024
- MediWound Announces $25 Million Strategic Private Placement Financing - July 16th, 2024
- Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair - July 16th, 2024
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - July 16th, 2024
- Kraig Biocraft Laboratories Completes Phase One of its Spider Silk Production Facility Expansion - July 16th, 2024
- Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with... - July 16th, 2024
- Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic... - July 16th, 2024
- Rectify Pharmaceuticals Appoints Bharat Reddy as Chief Business Officer - July 16th, 2024
- Spectral AI Continues Support of Naked Short Selling Inquiry - July 16th, 2024
- Milestone Pharmaceuticals Refreshes Board of Directors - July 16th, 2024
- New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure - July 16th, 2024
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 21st, 2023
- Cardiac stem cells: Current knowledge and future prospects - April 13th, 2023
- Stem cell therapies in cardiac diseases: Current status and future ... - April 13th, 2023
- Stem Cell and Regenerative Biology | Johns Hopkins Heart and Vascular ... - April 13th, 2023
- Center for Regenerative Biotherapeutics - Cardiac Regeneration - April 13th, 2023
- MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 25th, 2023
- CAREDX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 1st, 2023
- A Possible Connection between Mild Allergic Airway Responses and Cardiovascular Risk Featured in Toxicological Sciences - Newswise - February 4th, 2023
- Baby's life saved by surgeon who carried out world's first surgery ... - December 25th, 2022
- An organoid model of colorectal circulating tumor cells with stem cell ... - December 25th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - December 1st, 2022
- Stem-cell niche - Wikipedia - December 1st, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Scientists Spliced Human Brain Tissue Into The Brains of Baby Rats - ScienceAlert - October 13th, 2022
- Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution | Communications Biology - Nature.com - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine -... - October 13th, 2022
- Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co - TheHealthSite - October 5th, 2022
- 'Love hormone' oxytocin could help reverse damage from heart attacks via cell regeneration - Study Finds - October 5th, 2022
- Recapitulating Inflammation: How to Use the Colon Intestine-Chip to Study Complex Mechanisms of IBD - Pharmaceutical Executive - September 27th, 2022
- Adult Stem Cells // Center for Stem Cells and Regenerative Medicine ... - September 19th, 2022
- CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease - Cardiovascular Diabetology - Cardiovascular... - September 19th, 2022
- Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and... - September 19th, 2022
- Neural crest - Wikipedia - September 3rd, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 3rd, 2022
- Discover the Mental and Physical Health Benefits of Fasting - Intelligent Living - September 3rd, 2022
- Heart Association fellowship to support research - Binghamton - August 26th, 2022
- Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration | Communications Biology -... - August 26th, 2022
- High intensity interval training protects the heart against acute myocardial infarction through SDF-1a, CXCR4 receptors and c-kit levels - Newswise - August 26th, 2022
- Yale University: Uncovering New Approaches to a Common Inherited Heart Disorder | India Education - India Education Diary - August 10th, 2022
- Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery | International Journal of Obesity -... - August 10th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 10th, 2022
- Protocol for a Nested, Retrospective Study of the Australian Placental Transfusion Study Cohort - Cureus - August 10th, 2022
- Autologous Cell Therapy Market Size to Grow by USD 4.11 billion, Bayer AG and Brainstorm Cell Therapeutics Inc. Among Key Vendors - Technavio - PR... - August 2nd, 2022
- UTSW researcher part of team awarded $36 million heart research grant - The Dallas Morning News - August 2nd, 2022
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News - August 2nd, 2022
- Hyperglycaemia-Induced Impairment of the Autorhythmicity and Gap Junction Activity of Mouse Embryonic Stem Cell-Derived Cardiomyocyte-Like Cells -... - July 25th, 2022
- NASA's Solution to Stem Cell Production is Out of this World - BioSpace - July 25th, 2022
- Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor | Signal Transduction and Targeted Therapy - Nature.com - July 25th, 2022
- 'My Teen Sweetheart And I Drifted Apart. 30 Years Later I Made a Shocking Discovery' - Newsweek - July 25th, 2022
- EU: New Blood? Proposed Revisions to the EUs Blood, Tissues and Cells Rules - GlobalComplianceNews - July 25th, 2022
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema - July 25th, 2022
- Cell Separation Technologies Market Expands with Rise in Prevalence of Chronic Diseases, States TMR Study - GlobeNewswire - July 25th, 2022
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK - July 25th, 2022
- Stem Cells Used to Repair Heart Defects in Children - NBC 5 Dallas-Fort Worth - July 16th, 2022
- Pneumonia and Heart Disease: What You Should Know - Healthline - July 16th, 2022
- Promising solution to fatal genetic-disorder complications discovered by University professor and Ph.D. candidate - Nevada Today - July 16th, 2022
- Current and advanced therapies for chronic wound infection - The Pharmaceutical Journal - July 16th, 2022
- Why do some women struggle to breastfeed? A UCSC researcher on what we know, and don't - Lookout Santa Cruz - July 16th, 2022
- Mesenchymal stem cells: from roots to boost - PMC - July 8th, 2022
- New study allows researchers to more efficiently form human heart cells from stem cells - University of Wisconsin-Madison - July 8th, 2022
- Dr Victor Chang saved hundreds of lives. 31 years ago today, he was murdered. - Mamamia - July 8th, 2022
- Exosome Therapeutics Market Research Report Size, Share, New Trends and Opportunity, Competitive Analysis and Future Forecast Designer Women -... - July 8th, 2022
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace - July 8th, 2022
- Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and... - July 8th, 2022
- What New Advances are there in 3D Bioprinting Tissues? - AZoM - June 30th, 2022